Limitations in the evidence used by widely-consulted reference compendia to support off-label use of Roche/Astellas Pharma Inc.’s oncology drug Tarceva (erlotinib) demonstrate the weaknesses in the current system, researchers with the University of North Carolina Lineberger Comprehensive Cancer Center argue in an opinion piece published in the Journal of the American Medical Association Oct. 18.
The Medicare program and private payers have used third-party compendia to inform coverage decisions for off-label cancer drugs in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?